12040 results for "cancer rna-seq"

in 38.21 milliseconds.

• TPM for IMpower133 (GO30081)

  This dataset contains log2(TPM + 1) for 271 tumor samples profiled by RNA-seq for the entire transcriptome for samples originating from IMpower133 (GO30081).

  Dataset EGAD50000000196

• RNA-seq data of CRC-PDX tumors after drug treatment

  We obtained bulk RNAseq data of CRC-PDX tumors after administration of drug or vehicle to clarify the mechanisms of action.

  Dataset EGAD50000000849

• Convergent genetic adaptation in human tumors developed under systemic hypoxia and in populations living at high altitudes

  Genomic files, including whole-exome and RNA-seq data from tumors and cell lines, were generated and analyzed in this study.

  Dac EGAC50000000484

• RNA-seq of murine osteosarcoma cell line genetically modified for CYR61

  Transcriptomic analysis of K7M2 murine osteosarcoma cells stably modified to overexpress or repress CYR61

  Study EGAS50000000526

• Melanoma transcriptome profiling

  This dataset includes transcriptome profiling of 68 early-passage metastatic melanoma cell lines. The data are provided as paired-end RNA seq fastq files.

  Dataset EGAD00001006270

• Melanoma microRNA profiling

  This dataset includes microRNA profiling of 61 early-passage metastatic melanoma cell lines. The data are provided as single-end small RNA seq fastq files.

  Dataset EGAD00001006269

• HDAC inhibitor quisinostat in synovial sarcoma cell lines

  An RNA Seq study of the effects of HDAC inhibitor Quisinostat on six different synovial sarcoma cell lines

  Dataset EGAD00001003810

• TenK10K project

  This DAC handles access to data from the TenK10K project, which is comprised of matched whole-genome sequencing (WGS), single cell RNA-sequencing (scRNA-seq), single nuclei ATAC-sequencing, and single cell Multiome datasets.

  Dac EGAC50000000931

• Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens

  Tumor molecular profiling is becoming a standard of care for patients with cancer, but the optimal platform for cancer sequencing remains undetermined. We established a comprehensive assay, the Todai OncoPanel (TOP), which consists of DNA and RNA hybridization capture-based next-generation sequencing panels. A novel method for target enrichment, named the junction capture method, was developed for the RNA panel to accurately and cost-effectively detect 365 fusion genes as well as aberrantly spliced transcripts. The TOP RNA panel can also measure the expression profiles of an additional 109 genes. The TOP DNA panel was developed to detect single nucleotide variants and insertions/deletions for 464 genes, to calculate tumor mutation burden and microsatellite instability status, and to infer chromosomal copy number. Clinically relevant somatic mutations were identified in 32.2% (59/183) of patients by prospective TOP testing, signifying the clinical utility of TOP for providing personalized medicine to cancer patients.

  Study JGAS000164

• ChIP-Seq (H3K4me3, H3K4me1, H3K9me3, H3K27ac, H3K27me3, H3K36me3, Input) data for HL60 cell line generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency.

  ChIP-Seq (H3K4me3, H3K4me1, H3K9me3, H3K27ac, H3K27me3, H3K36me3, Input) data for HL60 cell line generated at Centre for Epigenome Mapping Technologies, Genome Sciences Center, B.C. Cancer Agency.

  Dataset EGAD00001002238